PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
264.51%
Other expenses growth above 1.5x CRVO's 100.00%. Michael Burry would check for concerning trends.
3.15%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
3.15%
Total costs growth less than half of CRVO's 15.98%. David Dodd would verify sustainability.
-0.34%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-75.00%
Both companies reducing D&A. Martin Whitman would check industry patterns.
15.50%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
16.24%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-3.90%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
Tax expense change of 3.90% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
12.65%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
12.55%
EPS growth while CRVO declines. John Neff would investigate advantages.
12.55%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.